



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/026,992
Confirmation No.: 2621
Filing Date: December 19, 2001
Examiner: Deepak R. Rao
Group Art Unit: 1624
Applicants: Bebbington, et al.
For: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE
INHIBITORS

February 28, 2006
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copy(ies) of references Citation No(s). B5, C1-C5 are attached.
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.

- (b) ☐ No fee is believed due because:

- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.


Applicants: Bebbington, et al.
Application No.: 10/026,992

- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

Applicants: **Bebbington, et al.**
Application No.: **10/026,992**

- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,



Jennifer G. Che, Reg. No. 58,035
Agent for Applicants
Lisa A. Dixon, Reg. No. 40,995
Attorney for Applicants
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6525
Fax: (617) 444-6483
Customer No. 27916



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/026,992
	Filing Date	December 19, 2001
	First Named Inventor	David Bebbington
	Group Art Unit	1624
	Examiner Name	Deepak R. Rao
	Attorney Docket Number	VPI/00-130-4 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B5	WO 2004/013140	Vertex Pharmaceuticals, Incorporated	Feb. 12, 2004		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Bischoff et al., "A homologue of <i>Drosophila aurora</i> kinase is a oncogenic and amplified in human colorectal cancers" EMBO J., 1998, 17, 3052-3065.
	C2	Bischoff et al., "The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis" Trends in Cell Biology, 1999, 9, 454-459.
	C3	Cline et al., "Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (<i>fa/fa</i>) Rats" <i>Diabetes</i> 51: 2903-2910, 2002.
	C4	Henriksen et al., "Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats" <i>J. Physiol. Endocrinol. Metab.</i> 284: E892-E900, 2003.
	C5	Harrington, et al, "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth <i>in vivo</i> " <i>Nature Medicine</i> 10, 262-267 (2004).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.